Loading...
Loading...
AWH| Name | Value |
|---|---|
| Revenues | 2.1M |
| Cost of Revenue | 0.9M |
| Gross Profit | 1.2M |
| Operating Expense | 10.9M |
| Operating I/L | -9.7M |
| Other Income/Expense | 5.1M |
| Interest Income | 0.0M |
| Pretax | -4.6M |
| Income Tax Expense | -5.1M |
| Net Income/Loss | 0.6M |
Aspira Women's Health Inc. develops and commercializes diagnostic tests for gynecologic disease, offering OVA1, OVERA, and OVA1plus to detect ovarian malignancy risk in women with adnexal masses, as well as ASPiRA GenetiX for gynecologic cancer risk. The company also operates Aspira Synergy, a testing platform and cloud service, and ASPiRA LABS, specializing in biomarker-based technologies for gynecologic cancers. Its pipeline products include OVAWatch, EndoCheck, and OVAInherit. Aspira Women's Health Inc. serves physicians, laboratories, and has collaborations with Baylor Genetics, Harvard Dana-Farber Cancer Institute, Brigham and Women's Hospital, Medical University Lodz, and a strategic alliance with Quest Diagnostics, Incorporated.
